Ivermectin Useless In Covid Treatment And Causes Diarrhea According To Malaysian Trials

source – the edge markets
  • Ivermectin does not reduce the risk of serious disease from COVID-19 in stage two and three patients.

  • The safety analysis reported a threefold occurrence of side effects among the (Ivermectin) group, compared with the (standard of care) group, of which most of them were diarrhea cases.

  • Medical practitioners cautioned not to spread ads or illegally sell Ivermectin to patients until more scientifically sound data is available.

Ivermectin Useless In Covid Treatment And Causes Diarrhea According To Malaysian Trials

According to Malaysia’s Health Ministry, Ivermectin does not reduce the risk of serious disease from COVID-19 and cannot be recommended for inclusion in established COVID-19 treatment recommendations.

Dr. Noor Hisham Abdullah, Director-General of Health, said on Wednesday (Nov 3) that the ministry recommended that Ivermectin be used exclusively in clinical trials with monitoring, citing the findings of the Institute for Clinical Research’s I-TECH research (ICR).

The research included 500 COVID-19 patients admitted to the hospital in stage two or stage three categories. It assessed the effectiveness of a treatment course of five days of Ivermectin.

“The clinical trial study was conducted by infectious disease physicians and clinicians who were actively involved in COVID-19 management in collaboration with ICR under the National Institute of Health," he said.

“The I-TECH study was to see whether the administration of Ivermectin in the first week on patients experiencing symptoms of COVID-19 could prevent them from getting worse (stage four or stage five) which was among patients aged 50 years and above and having at least one comorbidity."

One set of patients received Ivermectin therapy, while the other received normal care in accordance with the health ministry’s guidelines.

Dr. Steven Lim Chee Loon, an infectious disease specialist at Ipoh’s Raja Permaisuri Bainun Hospital, revealed that there was no significant difference between the two groups in terms of ICU admission, use of respiratory support equipment, symptom recovery, blood test parameters, and chest X-ray scans.

“The probability to fully recover from the symptoms on the fifth day among the two groups was almost similar, where there was no statistically significant difference recorded," Dr Noor Hisham added.

“Apart from that, the safety analysis reported a threefold occurrence of side effects among the (Ivermectin) group, compared with the (standard of care) group, of which most of them were diarrhea cases.”

“It is hoped that the local study could provide enlightenment to medical practitioners in Malaysia and the public who have been asking about the efficacy of Ivermectin in the COVID-19 clinical treatment practice."

source - UConn

He further cautioned medical practitioners not to encourage the use of Ivermectin for COVID-19 treatment, including spreading ads or illegally selling Ivermectin, until more scientifically sound data is available.

Dr Hisham also highlighted that the study’s findings are consistent with large-scale studies such as IVERCOR-COVID-19 from Argentina and TOGETHER from Brazil, which do not support the routine use of Ivermectin in COVID-19 treatment.

He stated that the I-TECH research team intended to submit the study data for publication in a peer-reviewed journal in order to provide further data on Ivermectin trials, including meta-analysis.

Total
18
Shares
Previous Post

Food Operators Urge ‘Karens’ and ‘Kens’ To Follow SOPs

Next Post

Over 1000 Cases of Delta Variant Of Concern Detected Says Health Ministry

Related Posts
Total
18
Share